Filing Details

Accession Number:
0001415889-24-020265
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-07-29 17:39:59
Reporting Period:
2024-07-25
Accepted Time:
2024-07-29 17:39:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Enliven Therapeutics Inc. ELVN Pharmaceutical Preparations (2834) 811523849
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1967168 Samuel Kintz C/O Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder CO 80301
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-07-25 3,793 $24.53 1,071,732 No 4 S Indirect See footnote
Common Stock Disposition 2024-07-25 8,164 $25.10 1,063,568 No 4 S Indirect See footnote
Common Stock Disposition 2024-07-25 43 $25.83 1,063,525 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 88,531 Indirect See footnote
Common Stock 88,531 Indirect See footnote
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
  2. This transaction was executed in multiple trades at prices ranging from $23.81 to $24.8005. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
  4. This transaction was executed in multiple trades at prices ranging from $24.81 to $25.7811. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  5. This transaction was executed in multiple trades at prices ranging from $25.8172 to $25.8413. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  6. The shares are held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's elder son and for which the Reporting Person serves as an investment advisor.
  7. The shares are held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's younger son and for which the Reporting Person serves as an investment advisor.